Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria [0.03%]
从crovalimab转换为iptacopan治疗阵发性夜间血红蛋白尿症后的贫血和症状改善
Daisuke Ogiya,Sawako Shiraiwa,Seina Koyama et al.
Daisuke Ogiya et al.
Objectives: Paroxysmal nocturnal hemoglobinuria (PNH) may develop breakthrough hemolysis (BTH) despite C5 inhibition. Although iptacopan, an oral factor B inhibitor, has demonstrated efficacy in phase 3 trials, switching ...
Age-dependent clinical, molecular, and prognostic differences in patients with AML: a retrospective study [0.03%]
急性髓系白血病患者临床特点、分子特征及预后的年龄差异性分析：一项回顾性研究
Hong Liu,Zhi Li,Jingjing Ma et al.
Hong Liu et al.
Objectives: This study aimed to compare clinical, and molecular features between acute myeloid leukemia (AML) patients aged
Effect of autoimmune diseases on aplastic anemia: a bidirectional two-sample Mendelian randomization study [0.03%]
自身免疫性疾病对再生障碍性贫血的影响：双向两样本孟德尔随机化研究
Qiuni Chen,Chuanyang Lu,Chunling Wang et al.
Qiuni Chen et al.
Objectives: Numerous observational research avenues have identified a possible correlation between aplastic anemia and autoimmune diseases, rooted in analogous dysfunctional immune responses. Nevertheless, causal link bet...
Clinical characteristics and whole exome sequencing in JAK2 V617F- and CALR-unmutated essential thrombocythemia [0.03%]
JAK2 V617F和CALR阴性原发性血小板增多症的临床特征和外显子组测序研究
Siraphop Thammayot,Patcharawadee Thongkumkoon,Jeerawan Klangjorhor et al.
Siraphop Thammayot et al.
Objectives: The aim of this study was to characterize the clinical features and outcomes of patients with JAK2 V617F- and CALR-unmutated essential thrombocythemia (ET) and to identify potential driver mutations through wh...
Knowledge, attitude and practices regarding blood donation and its determinants among pre-service trainees at Finote Selam College of Education, Northwest Ethiopia [0.03%]
埃塞俄比亚芬特塞拉姆教育学院师范生献血知识、态度和行为及其影响因素调查研究
Solomon Tsehay Mengistie
Solomon Tsehay Mengistie
Introduction: Blood is vital for life, but ensuring a safe and sufficient supply remains a public health challenge, particularly in low-resource settings. This study explores the knowledge, attitudes, practices, and facto...
Independent prognostic factors predicting survival in multiple myeloma patients post-chemotherapy: a retrospective study [0.03%]
化疗后多发性骨髓瘤患者的独立预后因素：一项回顾性研究
Yuan Luo,Tao Jiang,Li Liu
Yuan Luo
Objective: To identify simple clinical predictors of prognosis in multiple myeloma (MM) after chemotherapy and assess their predictive value. Methods: ...
Factors influencing anticoagulation control of patients on warfarin therapy at Windhoek Central Hospital's Warfarin Clinic [0.03%]
温得和克中央医院华法林门诊患者抗凝控制不佳的影响因素分析
Moses Mukwipure Thikukutu,Lauren Jenifer Jonkman,Bonifasius Siyuka Singu et al.
Moses Mukwipure Thikukutu et al.
Background: Thrombotic diseases are a global challenge. Warfarin remains the anticoagulant of choice in low- and middle-income countries. In 2017, a study reported suboptimal anticoagulation control of 29.4%, compared to the target of ≥ 65...
Leukemia-derived exosomes induce immunosuppression of dendritic cell function via TGFB2-MRPL58 axis [0.03%]
白血病源外泌体通过TGFB2-MRPL58轴诱导树突状细胞免疫抑制功能增强
Jinglong Lv,Yang Tao,Hui Zhong et al.
Jinglong Lv et al.
Objectives: To elucidate the mechanisms by which leukemia-derived exosomes induce immunosuppression in dendritic cells (DCs) and identify potential therapeutic targets. ...
Molecular and clinical characterization of -α4.2 subtypes in Shenzhen, Southern China [0.03%]
中国南部深圳地区-α4.2亚型的分子及临床特征分析
Lijuan Wang,Yaqin Song,Hui Gao et al.
Lijuan Wang et al.
Objectives: The 4.2-kb deletion (-α4.2) is a common cause of α-thalassemia in southern China. However, the molecular characteristics and clinical phenotypes of its subtypes remain incompletely characterized. This study ...
The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis [0.03%]
CAR-T疗法治疗复发或难治多发性骨髓瘤疗效和安全性的系统评价和meta分析
Yiwei Zhou,Xueqi Xie,Kai Feng et al.
Yiwei Zhou et al.
Objectives: The introduction of novel therapies has markedly improved the prognosis of multiple myeloma (MM), yet relapse remains common. For patients with relapsed or refractory multiple myeloma (RRMM), immunotherapy - particularly chimeri...